It is interesting to postulate that an ADAM17 inhibitor may be beneficial for breast cancer patients who are not responding to trastuzumab who also express low levels of HER2 because it would increase membrane-bound Nrg1 and prevent it from binding and activating HER3. The gene discussed is NRG1; the disease is breast carcinoma.